[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577145":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":14,"locations":20,"responsibleParty":39,"collaborators":10,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":10,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":23,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"University Medical Center Goettingen","OTHER",[8,11],{"label":9,"type":10,"description":10,"interventionNames":10},"CMT patients",null,{"label":12,"type":10,"description":13,"interventionNames":10},"Controls","Healthy age-matched controls",[15],{"name":16,"role":17,"phone":18,"phoneExt":10,"email":19},"Michael W Sereda, Prof. MD","CONTACT","+49 551 3964162","sereda@mpinat.mpg.de",[21],{"facility":22,"status":23,"city":24,"state":25,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"University Medical Centre","RECRUITING","Göttingen","Lower Saxony","37075","Germany","DE",{"type":30,"coordinates":31},"Point",[32,33],9.93228,51.53443,{"lat":33,"lon":32},[36],{"name":37,"role":17,"phone":18,"phoneExt":10,"email":38},"Lisa Reinecke, Dr.","lisa.reinecke@med.uni-goettingen.de",{"type":40,"investigatorFullName":41,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Michael W Sereda, MD, Professor of Neurology","Prof. Michael Sereda MD","100577145","longitudinal-biomarkers-with-selected-outcome-measures-in-cmt-100577145",false,"NCT06794489","Longitudinal Biomarkers With Selected Outcome Measures In CMT","CMT-BIO-Extend","Inclusion Criteria:\n\n* Clinical CMT Diagnosis \u002F Anamnestically Healthy Control Group\n* Genetic confirmation of CMT in adult patients\n* Ability to achieve the outcome measure at baseline\n* Age between 18 and 65 years\n* Capacity of all study participants to consent and signed informed consent, including patient or participant information and consent form\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding period\n* Other relevant neurological or psychiatric disorders, acute or in the past history\n* Presence of a serious previous internal disease",true,"ALL","18 Years","65 Years",{"count":55,"type":56},75,"ESTIMATED","OBSERVATIONAL","The goal of this study is to better understand the progression of CMT1A and identify risk factors influencing disease course. CMT1A, the most common hereditary peripheral neuropathy, shows high variability in individual phenotypes despite genetic similarity. Key objectives include analyzing determinants of phenotypic expression and documenting symptom variability over five years to capture disease dynamics.\n\nAlthough incurable, novel CMT therapies are in development. Proving efficacy is challenging due to slow progression and limited sensitive outcome measures. This study aims to validate biomarkers (DNA\u002Fepigenetics and RNA\u002FRT-PCR) and sensitive outcome measures from blood and skin of CMT patients over five years to support clinical therapy trials. Approximately 25 healthy volunteers will serve as controls, providing blood and skin samples for biomarker validation.\n\nAdditionally, the project will build a tissue collection (skin, blood, and cultured fibroblasts) from CMT patients of various subtypes for unrestricted scientific research, especially for the German CMT-NET network (NCT03386266). Scientific partners have free access to samples and data for research (commercial use is excluded). Currently, this collection includes over 100 standardized skin biopsies from CMT1A patients and is Germany's only repository for hereditary neuropathy tissue samples.",[60,61,62,63],"CMT1A","CMT (Charcot Marie Tooth Disease)","CMT 1A","CMT - Charcot-Marie-Tooth Disease",[65,66],"biomarkers","outcome measures","2026-03-05",{"date":69,"type":70},"2026-03-09","ACTUAL",{"date":72,"type":70},"2024-11-06",{"date":74,"type":56},"2026-07-05",{"name":5,"class":6},1]